BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Hepion Pharmaceuticals, Inc. HEPA
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-0.88
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-2058.6%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 13-year series below
Revenue
Net income
Per share
USD -0.88
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-2058.6%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-353.5%
Each USD of equity lost 2059 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.1M
total assets, end of FY2025
Total assetsUSD 3.1M
EquityUSD 2.7M
CashUSD 1.8M
Current ratio10.25×
Equity funds 87% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
·
·
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
−0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
·
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.88
−107.35
−616.07
−11.90
−0.47
−2.10
−6.11
−97.35
·
−2.41
−0.63
−1.02
−0.41
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−2058.6
−487.0
−171.3
−59.1
−49.0
−72.5
−81.2
−348.2
−205.0
−287.0
−714.7
−5672.2
·
Shares out B
0.01
0.00
0.00
0.00
0.08
0.03
0.00
0.00
0.01
0.08
0.03
0.02
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
38 of 38
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed